Literature DB >> 8062846

Thallium and indium antimyosin dual-isotope single-photon emission tomography in acute myocardial infarction to identify patients at further ischaemic risk.

H Schoeder1, H Topp, M Friedrich, A Jatzkewitz, M Roser.   

Abstract

Dual-isotope single-photon emission tomography (SPET) with indium-111 antimyosin and thallium-201 chloride was performed in 54 patients with acute myocardial infarction (AMI) to detect the location and extent of myocardial necrosis (antimyosin) and viable myocardium (201Tl). All patients underwent intravenous thrombolytic therapy with either streptokinase (1.5 million units/90 min) or tissue plasminogen activator (80 mg/90 min). Sensitivity in detecting MI was 91% (49/54 patients). With regard to dual-isotope SPET patterns, patients were divided into three groups: match, i.e. antimyosin uptake in segments with thallium defect (n = 8); mismatch, i.e. no uptake of either of the nuclides in corresponding segments (presence of perfusion abnormalities in the absence of antimyosin uptake) (n = 5); and overlap, i.e. thallium uptake in segments with uptake of antimyosin (n = 41). Coronary angiography and thallium exercise tests were performed in 40 and 45 patients, respectively, 5-14 days after MI. Exercise-induced ischaemia occurred in 66% of patients with overlap, 14% with match and 0% with mismatch (P < 0.05 for overlap vs other groups). If, however, major in-hospital complications (sudden cardiac death, severe arrhythmias; five overlap, three overlap in addition to match/mismatch, two match, two mismatch) were included in the statistical analysis, there was no significant difference between the three groups (P = NS). Thus, although the dual-isotope pattern "overlap" identifies a subgroup of patients with a substantial amount of residual viable tissue after MI and a high probability of exercise-induced ischaemia, this criterion is of limited value in assessing short-term prognosis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8062846     DOI: 10.1007/bf00171416

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  39 in total

1.  TIMI IIB follow-up. Lessons for clinicians and investigators.

Authors:  R M Califf; C Granger
Journal:  Circulation       Date:  1992-02       Impact factor: 29.690

2.  Indium-111 antimyosin scintigraphy to assess myocardial damage in patients with suspected myocarditis and cardiac rejection.

Authors:  I Carrió; L Berná; M Ballester; M Estorch; D Obrador; M Cladellas; L Abadal; M Ginjaume
Journal:  J Nucl Med       Date:  1988-12       Impact factor: 10.057

3.  High prevalence of myocardial monoclonal antimyosin antibody uptake in patients with chronic idiopathic dilated cardiomyopathy.

Authors:  D Obrador; M Ballester; I Carrió; L Bernà; G Pons-Lladó
Journal:  J Am Coll Cardiol       Date:  1989-05       Impact factor: 24.094

4.  Significance of fill-in after thallium-201 reinjection following delayed imaging: comparison with regional wall motion and angiographic findings.

Authors:  N Tamaki; H Ohtani; Y Yonekura; R Nohara; H Kambara; C Kawai; K Hirata; T Ban; J Konishi
Journal:  J Nucl Med       Date:  1990-10       Impact factor: 10.057

5.  Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.

Authors: 
Journal:  N Engl J Med       Date:  1989-03-09       Impact factor: 91.245

6.  Antimyosin antibody cardiac imaging: its role in the diagnosis of myocarditis.

Authors:  G W Dec; I Palacios; T Yasuda; J T Fallon; B A Khaw; H W Strauss; E Haber
Journal:  J Am Coll Cardiol       Date:  1990-07       Impact factor: 24.094

7.  A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction.

Authors:  E J Topol; R M Califf; B S George; D J Kereiakes; C W Abbottsmith; R J Candela; K L Lee; B Pitt; R S Stack; W W O'Neill
Journal:  N Engl J Med       Date:  1987-09-03       Impact factor: 91.245

8.  Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging.

Authors:  V Dilsizian; T P Rocco; N M Freedman; M B Leon; R O Bonow
Journal:  N Engl J Med       Date:  1990-07-19       Impact factor: 91.245

9.  GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.

Authors: 
Journal:  Lancet       Date:  1990-07-14       Impact factor: 79.321

10.  A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days.

Authors: 
Journal:  N Engl J Med       Date:  1986-06-05       Impact factor: 91.245

View more
  5 in total

Review 1.  Multiplexed imaging in cancer diagnosis: applications and future advances.

Authors:  Hisataka Kobayashi; Michelle R Longmire; Mikako Ogawa; Peter L Choyke; Satomi Kawamoto
Journal:  Lancet Oncol       Date:  2010-03-24       Impact factor: 41.316

Review 2.  Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals.

Authors:  Hisataka Kobayashi; Michelle R Longmire; Mikako Ogawa; Peter L Choyke
Journal:  Chem Soc Rev       Date:  2011-05-23       Impact factor: 54.564

3.  Prognosis after acute myocardial infarction.

Authors:  T M Krause; E A Moser
Journal:  Eur J Nucl Med       Date:  1994-11

4.  Simultaneous dual-radionuclide imaging: are the images trustworthy?

Authors:  J M Links
Journal:  Eur J Nucl Med       Date:  1996-10

5.  Prognostic evaluation of patients after myocardial infarction: incremental value of sestamibi single-photon emission computed tomography and echocardiography.

Authors:  P Zanco; A Zampiero; A Favero; N Borsato; F Chierichetti; D Rubello; G Ferlin
Journal:  J Nucl Cardiol       Date:  1997 Mar-Apr       Impact factor: 5.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.